Teoxane issues competing buyout bid for Revance and its Botox rival

Nicole DeFeudis

Editor

Revance Therapeutics’ contract dispute with a Swiss partner has caused hiccups in its plan to be acquired by Crown Laboratories. Now that partner says it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Teoxane issues competing buyout bid for Revance and its Botox rival

Nicole DeFeudis

Editor

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

FDA approves first drug to treat ultra-rare lipid storage disease

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA says Ozempic, Wegovy shortage is over

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Teox­ane is­sues com­pet­ing buy­out bid for Re­vance and its Botox ri­val

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Teoxane issues competing buyout bid for Revance and its Botox rival